Jazz Pharmaceuticals plc is a global biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines for neuroscience and oncology. The company's neuroscience portfolio is anchored by its sleep disorder franchise, which includes Xywav and Xyrem for the treatment of narcolepsy and idiopathic hypersomnia, as well as Epidiolex/Epidyolex, a cannabinoid-based therapy for severe forms of epilepsy acquired through its 2021 purchase of GW Pharmaceuticals. In oncology, Jazz offers treatments such as Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. The company generates the majority of its revenue from its neuroscience segment, which accounted for approximately $3.1 billion of its $4.3 billion total revenue in 2025, while the oncology segment contributed over $1.1 billion. Geographically, Jazz operates primarily in North America and Europe, with its corporate headquarters and legal domicile in Dublin, Ireland. The company's strategy relies heavily on targeted acquisitions and in-licensing to expand its therapeutic pipeline and commercial footprint.
